## CL: Colgate-Palmolive Company - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_20 -0.6% below STRENGTH zone (4.0-10.0%); PEG 3.10 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (51% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($75.27)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Colgate-Palmolive Stock Brushes Up Against Its Highs: Defensive Darling Or Overpolished Trade?**
- Source: AD HOC NEWS | 20260103T021617 | Bullish | Relevance: 100%
- Colgate-Palmolive's stock is trading near its 52-week high after a strong three-month run, driven by new innovations, cost initiatives, and investor confidence in its defensive qualities. Wall Street analysts are largely positive, with recommendations leaning towards Buy or Overweight, although some express caution about valuation. The company's future performance hinges on sustaining volume growth, managing input costs, and continuing to refresh its product lineup.

**2. Here's What to Expect From Colgate-Palmolive's Next Earnings Report**
- Source: inkl | 20260102T130745 | Somewhat-Bullish | Relevance: 100%
- Colgate-Palmolive (CL) is anticipated to announce its fiscal Q4 2025 results soon, with analysts projecting an adjusted EPS of $0.92, an increase of 1.1% year-over-year. The company has consistently surpassed Wall Street's earnings estimates in the preceding four quarters and maintains a "Moderate Buy" consensus rating from analysts, with an average price target indicating a potential upside of 9.9%. Despite share declines over the past year, Colgate-Palmolive showed strong Q3 2025 net sales and continues to hold significant global market share in oral care.

**3. Colgate-Palmolive (CL) target raised as analysts split on 2026 staples outlook**
- Source: MSN | 20260101T231046 | Somewhat-Bullish | Relevance: 100%
- Analysts are divided on the 2026 outlook for staples, specifically for Colgate-Palmolive (CL), despite a recent target price increase. The article mentions this split view and the target raise but does not provide details on the reasons behind the analyst divergence or the new target price.

**4. Colgate-Palmolive (CL) target raised as analysts split on 2026 staples outlook**
- Source: MSN | 20260103T030745 | Somewhat-Bullish | Relevance: 100%
- Analysts are divided on the 2026 outlook for staples companies, though Colgate-Palmolive (CL) recently saw its price target raised. This indicates a mixed sentiment within the analyst community regarding the future performance of the consumer staples sector.

**5. Colgate-Palmolive Stock Holds Its Ground As Defensive Trade Regains Shine**
- Source: AD HOC NEWS | 20260102T142130 | Bullish | Relevance: 100%
- Colgate-Palmolive's stock has shown quiet resilience, delivering steady gains and rewarding patient investors as defensive consumer staples regain favor. Supported by strong fundamentals, consistent dividend payouts, and positive analyst outlooks, the company continues to demonstrate pricing power and volume resilience in key categories like oral care and pet nutrition. While not a high-growth stock, its stability and reliable performance make it an attractive core holding for diversified portfolios.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $88 | $87 | +1% |
| 2025-12-11 | Argus Research | $0 | $0 | 0% |
| 2025-12-09 | RBC Capital | $88 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | main | Overweight |
| 2025-12-11 | Argus Research | down | Hold |
| 2025-12-09 | RBC Capital | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.8% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.2%)
- Blackrock Inc.: 8.6% (+0.5%)
- State Street Corpora: 6.0% (+0.2%)
- Price (T.Rowe) Assoc: 4.0% (-11.5%)
- Geode Capital Manage: 2.7% (+4.1%)

### Key Risks

1. Valuation stretched: PEG 3.1x requires aggressive growth execution.
2. Long-term trend broken: trading 8.8% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.10 signals overvaluation risk, limited margin of safety. Forward P/E 20.2x stretched relative to 5% growth. Quality metrics strong (ROE 294%, ROA 15%). Balance sheet: $1.1B free cash flow. Institutional flow bearish (5 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $62.8B |
| Beta | 0.29 |
| 52W Range | $74.55 - $100.18 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.10 |
| Forward P/E | 20.2 |
| Current P/E | 21.3 |
| YoY Growth | 5.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-1.0% over 5 days). Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). Below SMA200 (0.91x), long-term trend not supportive. RSI neutral at 44. Volume at 51% of 20MA suggests lack of conviction. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.55% (CS: 32) | Neutral |
| RSI_14 | 44.1 | Neutral |
| MACD Histogram | -0.04 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 0.990x | Below |
| vs SMA200 | 0.912x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $77.69
- **Stop Loss:** $75.27 (3.1% risk)
- **Target:** $80.11 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 495
- **Position Value:** $38,456.55
- **Portfolio %:** 38.46%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-01-30 (Est: $0.91)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.89 | $0.91 | +2.4% |
| 2025Q2 | $0.89 | $0.92 | +2.8% |
| 2025Q1 | $0.86 | $0.91 | +6.1% |
| 2024Q4 | $0.89 | $0.91 | +2.3% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*